Drugs / XKH004
Trials 0
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Comparator or background therapy1 trial | ||||||
| Phase 3 | NCT07498634 Comparator | Sep 2023 → Aug 2025 | — | Zhejiang Kanova Biopharmaceutical Co., LTD | Completed | No outcome recorded |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | XKH004 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT07498634 ↗ |
| Action | Inhibit | “Anti-human IL-17A/F” NCT07498634 ↗ |
| Modality | Monoclonal antibody | “Recombinant Anti-human IL-17A/F Humanized Monoclonal Antibody Injection” NCT07498634 ↗ |
| Route | Subcutaneous | “by subcutaneous injection” NCT07498634 ↗ |